Genelux Corp (GNLX)

$3.06 -0.02 (-0.65%)
Market Cap 127.54M
Revenue (ttm) 10,000.00
Net Income (ttm) -29.87M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -298,700.02%
Debt to Equity Ratio 0.00
Volume 189,144
Avg Vol 151,508
Day's Range N/A - N/A
Shares Out 37.74M
Stochastic %K 35%
Beta -0.34
Analysts Strong Sell
Price Target $17.60

Company Profile

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer and non-small cell lung cancer, as well as for liquid or solid tumors, appendiceal, colorectal and gastric cancers, other gynecologic malignancies, and periton...

Industry: Biotechnology
Sector: Healthcare
Phone: 805 267 9889
Address:
2625 Townsgate Road, Suite 230, Westlake Village, United States
KC1391
KC1391 Jul. 16 at 2:48 PM
$GNLX this going back to $2?
1 · Reply
Biotechnicity
Biotechnicity Jul. 15 at 1:39 PM
$GNLX Nice one-year chart he said to no one at all. Makes me feel like I’m chasing.
0 · Reply
Doozio
Doozio Jul. 15 at 3:49 AM
$GNLX a 🧠👀 in da FUTUre of 🧠⏰ out of 🐑⏰♾️ Roger is rocking LGNDary in RYTM 🐒🍌🧠⏰♾️
0 · Reply
Biotechnicity
Biotechnicity Jul. 14 at 5:41 PM
$GNLX I’m in.
0 · Reply
thesaltier1
thesaltier1 Jul. 11 at 1:14 PM
$GNLX a week or so of consolidation at this level would be healthy for next run up, bull flag if this consolidates in the 3.20 to 3.50 range
1 · Reply
Biotechnicity
Biotechnicity Jul. 11 at 2:27 AM
$GNLX looks enticing
0 · Reply
kshonstocks
kshonstocks Jul. 8 at 5:27 PM
$GNLX all over scans 100 dma b/o
0 · Reply
cllebye
cllebye Jul. 8 at 1:49 PM
$GNLX Eric Groen ,strong M&A acumen. Not a clinical or scientific hire but potentially deal structuring
1 · Reply
Kupper
Kupper Jul. 1 at 12:36 AM
$GNLX What year is this shit show going to end. They have been saying trial results are coming for years.
1 · Reply
Johnm_
Johnm_ Jun. 25 at 11:57 AM
$ALLR Trending $PRPH $GNLX $PHRRF
1 · Reply
Latest News on GNLX
Genelux Corporation Announces Appointment of Eric Groen as General Counsel, Corporate Secretary, Chief Compliance Officer and Head of Business Development

Jul 7, 2025, 7:00 AM EDT - 9 days ago

Genelux Corporation Announces Appointment of Eric Groen as General Counsel, Corporate Secretary, Chief Compliance Officer and Head of Business Development

Genelux Corporation Reports First Quarter 2025 Financial Results and Provides General Business Updates

May 6, 2025, 4:10 PM EDT - 2 months ago

Genelux Corporation Reports First Quarter 2025 Financial Results and Provides General Business Updates

Genelux Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Mar 28, 2025, 4:10 PM EDT - 3 months ago

Genelux Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Genelux Corporation Announces Pricing of $10.5 Million Underwritten Offering of Common Stock

Mar 25, 2025, 8:31 AM EDT - 4 months ago

Genelux Corporation Announces Pricing of $10.5 Million Underwritten Offering of Common Stock

Genelux Corporation Announces New Chief Financial Officer

Feb 3, 2025, 6:45 AM EST - 5 months ago

Genelux Corporation Announces New Chief Financial Officer

Genelux Corporation to Participate in a Fireside Chat with H.C. Wainwright

Dec 13, 2024, 7:01 AM EST - 7 months ago

Genelux Corporation to Participate in a Fireside Chat with H.C. Wainwright

Genelux Corporation to Participate in Fireside Chat at the Guggenheim Inaugural Healthcare Innovation Conference

Nov 6, 2024, 4:01 PM EST - 9 months ago

Genelux Corporation to Participate in Fireside Chat at the Guggenheim Inaugural Healthcare Innovation Conference

Genelux: 2nd Half Of 2025 PRROC Data Is Major Inflection Point

Oct 31, 2024, 10:59 AM EDT - 9 months ago

Genelux: 2nd Half Of 2025 PRROC Data Is Major Inflection Point

Genelux Corporation Announces First Patient Dosed in Phase 2 Trial Evaluating Systemic Therapy with Olvi-Vec in Non-Small Cell Lung Cancer

Oct 22, 2024, 4:01 PM EDT - 9 months ago

Genelux Corporation Announces First Patient Dosed in Phase 2 Trial Evaluating Systemic Therapy with Olvi-Vec in Non-Small Cell Lung Cancer

Genelux Corporation to Participate in the 2024 Maxim Healthcare Virtual Summit

Oct 9, 2024, 4:15 PM EDT - 10 months ago

Genelux Corporation to Participate in the 2024 Maxim Healthcare Virtual Summit

Genelux Corporation to Present at the H.C. Wainwright Global Investment Conference

Sep 3, 2024, 4:01 PM EDT - 11 months ago

Genelux Corporation to Present at the H.C. Wainwright Global Investment Conference

Genelux Corporation Reports Second Quarter 2024 Financial Results and Provides General Business Updates

Aug 14, 2024, 4:05 PM EDT - 1 year ago

Genelux Corporation Reports Second Quarter 2024 Financial Results and Provides General Business Updates

Genelux Corporation to Participate in Fireside Chat at BTIG's Virtual Biotechnology Conference 2024

Jul 30, 2024, 7:00 AM EDT - 1 year ago

Genelux Corporation to Participate in Fireside Chat at BTIG's Virtual Biotechnology Conference 2024

Genelux Corporation Announces Pricing of Approximately $27.5 Million Underwritten Offering of Common Stock and Accompanying Warrants

May 24, 2024, 8:00 AM EDT - 1 year ago

Genelux Corporation Announces Pricing of Approximately $27.5 Million Underwritten Offering of Common Stock and Accompanying Warrants

Genelux Corporation Announces Proposed Public Offering of Common Stock and Warrants

May 23, 2024, 4:01 PM EDT - 1 year ago

Genelux Corporation Announces Proposed Public Offering of Common Stock and Warrants

Genelux Corporation Reports First Quarter 2024 Financial Results and Provides General Business Updates

May 9, 2024, 4:25 PM EDT - 1 year ago

Genelux Corporation Reports First Quarter 2024 Financial Results and Provides General Business Updates

Genelux Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Apr 1, 2024, 7:00 AM EDT - 1 year ago

Genelux Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Genelux Corporation Receives FDA Fast Track Designation for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer

Nov 27, 2023, 7:00 AM EST - 1 year ago

Genelux Corporation Receives FDA Fast Track Designation for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer

Genelux Corporation Reports Third Quarter 2023 Financial Results and Provides General Business Updates

Nov 14, 2023, 5:50 PM EST - 1 year ago

Genelux Corporation Reports Third Quarter 2023 Financial Results and Provides General Business Updates

Genelux Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 14, 2023, 7:00 AM EDT - 1 year ago

Genelux Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Genelux: Biotech To Watch With Oncolytic Virus Immunotherapy In Late-Stage Testing

Aug 30, 2023, 1:56 PM EDT - 2 years ago

Genelux: Biotech To Watch With Oncolytic Virus Immunotherapy In Late-Stage Testing

Genelux Corporation Reports Second Quarter 2023 Financial Results and Provides General Business Updates

Aug 14, 2023, 7:00 AM EDT - 2 years ago

Genelux Corporation Reports Second Quarter 2023 Financial Results and Provides General Business Updates

Genelux Corporation to Participate in Fireside Chat at BTIG's Virtual Biotechnology Conference 2023

Aug 2, 2023, 4:00 PM EDT - 2 years ago

Genelux Corporation to Participate in Fireside Chat at BTIG's Virtual Biotechnology Conference 2023

Genelux Corporation Strengthens Senior Management and Clinical Team with Promotions and New Hires

Jul 20, 2023, 4:45 PM EDT - 2 years ago

Genelux Corporation Strengthens Senior Management and Clinical Team with Promotions and New Hires

Genelux: A Game Changer In Platinum-Resistant Ovarian Cancer

Jul 11, 2023, 4:12 AM EDT - 2 years ago

Genelux: A Game Changer In Platinum-Resistant Ovarian Cancer

Genelux Corporation Announces Publication of Phase I Trial Results of Intrapleural Administration of Olvi-Vec in Patients with Malignant Pleural Effusion from Mesothelioma, Lung or Breast Cancers in Frontiers in Immunology

Jul 10, 2023, 7:00 AM EDT - 2 years ago

Genelux Corporation Announces Publication of Phase I Trial Results of Intrapleural Administration of Olvi-Vec in Patients with Malignant Pleural Effusion from Mesothelioma, Lung or Breast Cancers in Frontiers in Immunology

Genelux Corporation and TVAX Biomedical, Inc. announce the issuance of a United States patent covering the combination of an adoptive T cell therapy/oncolytic viral cancer treatment that is exclusively licensed to V2ACT Therapeutics™, LLC

Jun 29, 2023, 7:00 AM EDT - 2 years ago

Genelux Corporation and TVAX Biomedical, Inc. announce the issuance of a United States patent covering the combination of an adoptive T cell therapy/oncolytic viral cancer treatment that is exclusively licensed to V2ACT Therapeutics™, LLC

Genelux Corporation Set to Join the Russell 3000® and Russell 2000® Indexes Effective June 26, 2023

Jun 22, 2023, 7:00 AM EDT - 2 years ago

Genelux Corporation Set to Join the Russell 3000® and Russell 2000® Indexes Effective June 26, 2023

Genelux Corporation Announces $18 Million Private Placement

Jun 12, 2023, 7:00 AM EDT - 2 years ago

Genelux Corporation Announces $18 Million Private Placement

Genelux Corporation Announces Publication of Positive Topline Data from Phase 2 VIRO-15 Trial Evaluating Olvimulogene Nanivacirepvec (Olvi-Vec) in Platinum-Resistant or Refractory Ovarian Cancer in the Journal of the American Medical Association (JAMA) On

May 25, 2023, 4:01 PM EDT - 2 years ago

Genelux Corporation Announces Publication of Positive Topline Data from Phase 2 VIRO-15 Trial Evaluating Olvimulogene Nanivacirepvec (Olvi-Vec) in Platinum-Resistant or Refractory Ovarian Cancer in the Journal of the American Medical Association (JAMA) On

Genelux Corporation Announces $33 Million Private Placement

May 15, 2023, 7:00 AM EDT - 2 years ago

Genelux Corporation Announces $33 Million Private Placement

Genelux: Recent IPO With Phase 3 Stage Oncolytic Virus Cancer Therapy

Mar 26, 2023, 10:50 PM EDT - 2 years ago

Genelux: Recent IPO With Phase 3 Stage Oncolytic Virus Cancer Therapy

Genelux Corporation to Ring Nasdaq Opening Bell on March 29, 2023

Mar 23, 2023, 7:00 AM EDT - 2 years ago

Genelux Corporation to Ring Nasdaq Opening Bell on March 29, 2023

Genelux IPO prices at bottom of range

Jan 26, 2023, 6:40 AM EST - 2 years ago

Genelux IPO prices at bottom of range

Genelux Corporation Announces Pricing of Initial Public Offering

Jan 25, 2023, 9:00 PM EST - 2 years ago

Genelux Corporation Announces Pricing of Initial Public Offering

IPO Update: Genelux Finalizes $16 Million IPO Plan

Sep 19, 2022, 1:49 PM EDT - 3 years ago

IPO Update: Genelux Finalizes $16 Million IPO Plan

Genelux sets IPO terms, as the biotech could be valued at up to $165 millino

Sep 19, 2022, 9:08 AM EDT - 3 years ago

Genelux sets IPO terms, as the biotech could be valued at up to $165 millino

KC1391
KC1391 Jul. 16 at 2:48 PM
$GNLX this going back to $2?
1 · Reply
Biotechnicity
Biotechnicity Jul. 15 at 1:39 PM
$GNLX Nice one-year chart he said to no one at all. Makes me feel like I’m chasing.
0 · Reply
Doozio
Doozio Jul. 15 at 3:49 AM
$GNLX a 🧠👀 in da FUTUre of 🧠⏰ out of 🐑⏰♾️ Roger is rocking LGNDary in RYTM 🐒🍌🧠⏰♾️
0 · Reply
Biotechnicity
Biotechnicity Jul. 14 at 5:41 PM
$GNLX I’m in.
0 · Reply
thesaltier1
thesaltier1 Jul. 11 at 1:14 PM
$GNLX a week or so of consolidation at this level would be healthy for next run up, bull flag if this consolidates in the 3.20 to 3.50 range
1 · Reply
Biotechnicity
Biotechnicity Jul. 11 at 2:27 AM
$GNLX looks enticing
0 · Reply
kshonstocks
kshonstocks Jul. 8 at 5:27 PM
$GNLX all over scans 100 dma b/o
0 · Reply
cllebye
cllebye Jul. 8 at 1:49 PM
$GNLX Eric Groen ,strong M&A acumen. Not a clinical or scientific hire but potentially deal structuring
1 · Reply
Kupper
Kupper Jul. 1 at 12:36 AM
$GNLX What year is this shit show going to end. They have been saying trial results are coming for years.
1 · Reply
Johnm_
Johnm_ Jun. 25 at 11:57 AM
$ALLR Trending $PRPH $GNLX $PHRRF
1 · Reply
Kupper
Kupper Jun. 24 at 2:56 PM
$GNLX up to 3.30 and back down to 2.78. WTF.
1 · Reply
Johnm_
Johnm_ Jun. 24 at 10:56 AM
$GNLX Update! Preliminary data from Genelux’s Phase 1b trial in platinum-relapsed/refractory small cell lung cancer (SCLC) shows early promise for Olvi-Vec immunochemotherapy. https://x.com/Genelux_Corp/status/1937231860674744489
0 · Reply
Johnm_
Johnm_ Jun. 20 at 5:12 PM
$PHRRF - Mover $ALLR $GNLX
0 · Reply
Johnm_
Johnm_ Jun. 18 at 5:52 PM
$ALLR - Break out ? $XBI $GNLX $PHRRF
0 · Reply
Johnm_
Johnm_ Jun. 18 at 10:29 AM
$ALLR Chart - Technical analysis, On alert. On my radar. $PRPH $GNLX $PHRRF
0 · Reply
Kupper
Kupper Jun. 17 at 3:55 PM
$GNLX shithead shorts at it again. What a pathetic group of miserable people.
0 · Reply
Kupper
Kupper Jun. 13 at 9:07 PM
$GNLX Irritating to see the attack of the shithead shorts as soon as this runs up.
0 · Reply
RunnerSignals
RunnerSignals Jun. 13 at 8:25 PM
comeback kings $GNLX soared $ELVN came alive $EU fueled up $GEVO sparked interest and $CLNE cleaned up with a tidy close
0 · Reply
Shakescene1
Shakescene1 Jun. 13 at 7:00 PM
$GNLX popin today - interesting - perhaps more frontline datasets on olvi vec? I don’t know
0 · Reply
Johnm_
Johnm_ Jun. 10 at 12:00 PM
$GNLX Genelux Corporation (GNLX) Upgraded to Buy: Here's What You Should Know https://finance.yahoo.com/news/genelux-corporation-gnlx-upgraded-buy-160007749.html
0 · Reply
Kupper
Kupper Jun. 4 at 3:21 PM
$GNLX time to buy more. Thanks idiots for bringing it down to my buy range again.
2 · Reply
Shakescene1
Shakescene1 Jun. 3 at 8:03 PM
$GNLX gonna rip in ‘26
0 · Reply